Literature DB >> 20573377

Comparison of validated instruments measuring sexual function in men.

Adam W Levinson1, Nicholas T Ward, Martin G Sanda, Lynda Z Mettee, John T Wei, Li-Ming Su, Mark S Litwin, Christian P Pavlovich.   

Abstract

OBJECTIVES: There is no universally accepted instrument to measure sexual function (SF) in men. We compare validated SF measures in a single cohort.
METHODS: We compare the Sexual Health Inventory for Men (SHIM), Expanded Prostate Cancer Index Composite SF domain (EPIC-SF), and a reconstructed University of California Los Angeles Prostate Cancer Index SF domain (PCI-SF) in 856 men scheduled for radical prostatectomy. We define potency thresholds for the PCI-SF and EPIC-SF.
RESULTS: Mean age, body mass index, Gleason sum, and PSA were 57 years, 26.7 kg/m(2), 6.3, and 5.9 ng/mL, respectively. Mean instrument scores were as follows: SHIM 20.1; EPIC-SF 65; PCI-SF 71. All instruments were significantly intercorrelated (r = 0.99 for EPIC-SF vs PCI-SF, r = 0.75 for SHIM vs EPIC-SF, r = 0.77 for SHIM vs PCI-SF, all P < .001). The SHIM had the greatest negative skew and ceiling effect (P < .001). Although high scores on either the EPIC-SF or PCI-SF translated reliably to high SHIM scores, the reverse was not true. Subjects who reported no erectile dysfunction (ED) on the SHIM (>or=22) had diverse overall SF, whereas those who scored highly on the EPIC-SF or PCI-SF had both excellent erectile function (potency) and overall SF (including orgasmic function, erectile function, and sexual desire). EPIC-SF scores >or=65 and PCI-SF scores >or=75 define men that are both potent and have good SF.
CONCLUSIONS: The SHIM is intended as an instrument to assess ED. It is, however, inadequate as a measure of overall SF. The EPIC-SF and PCI-SF capture gradations of both sexual and erectile function and may also be used to define potency more comprehensively. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20573377     DOI: 10.1016/j.urology.2010.04.033

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Prediction of erectile function following treatment for prostate cancer.

Authors:  Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.

Authors:  Emily A Vertosick; Andrew J Vickers; Janet E Cowan; Jeanette M Broering; Peter R Carroll; Matthew R Cooperberg
Journal:  J Urol       Date:  2017-03-22       Impact factor: 7.450

3.  Is a return to baseline sexual function possible? An analysis of sexual function outcomes following laparoscopic radical prostatectomy.

Authors:  Adam W Levinson; Hugh J Lavery; Nicholas T Ward; Li-Ming Su; Christian P Pavlovich
Journal:  World J Urol       Date:  2010-11-24       Impact factor: 4.226

4.  The Association Between Periodontitis and Erectile Dysfunction: A Systematic Review and Meta-Analysis.

Authors:  Fathima Farook; Azzam Al Meshrafi; Nuzaim Mohamed Nizam; Abdulsalam Al Shammari
Journal:  Am J Mens Health       Date:  2021 May-Jun

5.  Validation of Portuguese version of Quality of Erection Questionnaire (QEQ) and comparison to International Index of Erectile Function (IIEF) and RAND 36-Item Health Survey.

Authors:  Ana Luiza Reis; Leonardo Oliveira Reis; Ricardo Destro Saade; Carlos Alberto Santos; Marcelo Lopes de Lima; Adriano Fregonesi
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

Review 6.  Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men.

Authors:  Shunichi Namiki; Yoichi Arai
Journal:  Reprod Med Biol       Date:  2011-02-16

7.  Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Authors:  Leonard N Chen; Simeng Suy; Sunghae Uhm; Eric K Oermann; Andrew W Ju; Viola Chen; Heather N Hanscom; Sarah Laing; Joy S Kim; Siyuan Lei; Gerald P Batipps; Keith Kowalczyk; Gaurav Bandi; John Pahira; Kevin G McGeagh; Brian T Collins; Pranay Krishnan; Nancy A Dawson; Kathryn L Taylor; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-03-13       Impact factor: 3.481

8.  Potency preservation following stereotactic body radiation therapy for prostate cancer.

Authors:  Olusola Obayomi-Davies; Leonard N Chen; Aditi Bhagat; Henry C Wright; Sunghae Uhm; Joy S Kim; Thomas M Yung; Siyuan Lei; Gerald P Batipps; John Pahira; Kevin G McGeagh; Brian T Collins; Keith Kowalczyk; Gaurav Bandi; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-11-01       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.